AbbVie Inc. Book Value per Share Growth

Book Value per Share Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book Value per Share Growth growth rates and interactive chart.

Highlights and Quick Summary

  • Book Value per Share Growth for the quarter ending September 29, 2021 was -11.31% (a -45.02% decrease compared to previous quarter)
  • Year-over-year quarterly Book Value per Share Growth decreased by -104.83%
  • Annual Book Value per Share Growth for 2020 was 242.16% (a -35711.76% decrease from previous year)
  • Annual Book Value per Share Growth for 2019 was -0.68% (a -99.75% decrease from previous year)
  • Annual Book Value per Share Growth for 2018 was -271.62% (a -2415.6% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book Value per Share Growth of AbbVie Inc.

Most recent Book Value per Share Growthof ABBV including historical data for past 10 years.

Interactive Chart of Book Value per Share Growth of AbbVie Inc.

AbbVie Inc. Book Value per Share Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -11.31% -20.57% 254.79%
2020 234.26% 255.41% 254.54% 5.31% 242.16%
2019 -0.68% -187.32% -168.9% -336.78% -0.68%
2018 -271.62% -146.17% -157.13% -28.64% -271.62%
2017 11.73% 5.64% 8.48% 8.93% 11.73%
2016 17.73% 34.65% 2.22% 232.8% 17.73%
2015 122.28% 1.08% 3.79% -70.68% 122.28%
2014 -61.36% 29.45% 46.2% 58.14% -61.36%
2013 32.56% -77.36% -69.31% -75.63% 32.56%
2012 -71.67% 0.0% 0.0% 0.0% -71.82%
2011 0.0% 0.0% 0.0%
2010 0.0%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.